Market Overview:
The global hirudin market is expected to grow at a CAGR of 6.5% from 2018 to 2030. The growth in the market can be attributed to the increasing prevalence of thrombosis diseases, tumor diseases, and other applications. Additionally, the increasing demand for recombinant hirudin is also contributing to the growth of the global hirudin market. However, stringent regulatory requirements and high costs associated with R&D are restraining the growth of this market. On the basis of type, natural hirudin held a major share in 2017 and is expected to maintain its dominance during the forecast period. This can be attributed to its benefits such as easy availability and low cost as compared to recombinant hirudins.
Product Definition:
Hirudin is a naturally occurring protein found in the saliva of leeches. It is a powerful anticoagulant which inhibits blood clotting. Hirudin has been used clinically to prevent thrombosis and to dissolve blood clots.
Natural Hirudin:
Hirudin, also known as leukotriene B4 is a glycoprotein hormone with anti-inflammatory properties. It is produced by the liver in response to fat and sugar metabolism. The main functions of Hirudin are to maintain blood pressure and cholesterol levels, aid in digestion, help regulate the menstrual cycle among other functions.
Recombinant Hirudin:
Recombinant hirudin is a form of blood thinner. It is used to prevent bleeding during surgeries and dental procedures. The drug works by binding to the coagulation factor in the blood, which reduces the number of platelets in the blood.
Hirudin market has been witnessing strong growth over past few years on account of increasing demand for its usage in major surgical procedures such as gastrointestinal, orthopedic & neurosurgeries.
Application Insights:
The others segment held the largest market share in 2017. This segment includes conditions such as diabetes and kidney disease. The thrombosis disease segment is expected to witness the fastest growth during the forecast period due to its rising incidence globally. It is estimated that around 50,000 people die of thrombosis every year worldwide.
Thrombosis diseases include aplastic anemia, angina pectoris, stroke and pulmonary embolism among others. Increasing awareness about these diseases coupled with advanced treatment options is anticipated to boost product demand in the coming years.
Regional Analysis:
North America dominated the global market in 2017. The presence of a large number of companies coupled with high R&D expenditure and technological advancements are some factors contributing to its largest share. In addition, increasing demand for blood clotting products owing to rising incidence of cardiovascular diseases is expected to drive the regional market over the forecast period.
Asia Pacific is anticipated to witness lucrative growth during the forecast period owing to untapped opportunities in this region. Increasing healthcare spending by governments along with growing investments by pharmaceutical companies will boost revenue generation in this region over next eight years from 2018 till 2030 time frame). Rising geriatric population and prevalence of thrombosis & coagulation disorders are also driving regional growth rate significantly during same time frame).
Growth Factors:
- Increasing demand for blood thinners and anticoagulants owing to the increasing prevalence of cardiovascular diseases.
- Rising geriatric population, who are more susceptible to developing cardiovascular diseases and require blood thinners for prophylaxis.
- Growing popularity of Hirudin as an alternative to heparin in patients with heparin-induced thrombocytopenia (HIT).
- Increasing use of Hirudin in surgical procedures owing to its clot-dissolving properties.
Scope Of The Report
Report Attributes
Report Details
Report Title
Hirudin Market Research Report
By Type
Natural Hirudin, Recombinant Hirudin
By Application
Thrombosis Disease, Tumor Disease, Others
By Companies
The Medicines Company, Keyken, Minapharm, Abbott, SALUBRIS, Pfizer, Inc, Teva Pharmaceutical Industries Ltd, DUOPUTAI, Pentapharm
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
134
Number of Tables & Figures
94
Customization Available
Yes, the report can be customized as per your need.
Global Hirudin Market Report Segments:
The global Hirudin market is segmented on the basis of:
Types
Natural Hirudin, Recombinant Hirudin
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Thrombosis Disease, Tumor Disease, Others
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- The Medicines Company
- Keyken
- Minapharm
- Abbott
- SALUBRIS
- Pfizer, Inc
- Teva Pharmaceutical Industries Ltd
- DUOPUTAI
- Pentapharm
Highlights of The Hirudin Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Natural Hirudin
- Recombinant Hirudin
- By Application:
- Thrombosis Disease
- Tumor Disease
- Others
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Hirudin Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Hirudin is a protein that helps the body to break down and remove blood clots.
Some of the key players operating in the hirudin market are The Medicines Company, Keyken, Minapharm, Abbott, SALUBRIS, Pfizer, Inc, Teva Pharmaceutical Industries Ltd, DUOPUTAI, Pentapharm.
The hirudin market is expected to grow at a compound annual growth rate of 6.5%.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Hirudin Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Hirudin Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Hirudin Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Hirudin Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Hirudin Market Size & Forecast, 2020-2028
4.5.1 Hirudin Market Size and Y-o-Y Growth
4.5.2 Hirudin Market Absolute $ Opportunity
Chapter 5 Global Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Market Size Forecast by Type
5.2.1 Natural Hirudin
5.2.2 Recombinant Hirudin
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Market Size Forecast by Applications
6.2.1 Thrombosis Disease
6.2.2 Tumor Disease
6.2.3 Others
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Hirudin Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Hirudin Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Analysis and Forecast
9.1 Introduction
9.2 North America Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Market Size Forecast by Type
9.6.1 Natural Hirudin
9.6.2 Recombinant Hirudin
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Market Size Forecast by Applications
9.10.1 Thrombosis Disease
9.10.2 Tumor Disease
9.10.3 Others
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Analysis and Forecast
10.1 Introduction
10.2 Europe Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Market Size Forecast by Type
10.6.1 Natural Hirudin
10.6.2 Recombinant Hirudin
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Market Size Forecast by Applications
10.10.1 Thrombosis Disease
10.10.2 Tumor Disease
10.10.3 Others
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Market Size Forecast by Type
11.6.1 Natural Hirudin
11.6.2 Recombinant Hirudin
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Market Size Forecast by Applications
11.10.1 Thrombosis Disease
11.10.2 Tumor Disease
11.10.3 Others
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Analysis and Forecast
12.1 Introduction
12.2 Latin America Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Market Size Forecast by Type
12.6.1 Natural Hirudin
12.6.2 Recombinant Hirudin
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Market Size Forecast by Applications
12.10.1 Thrombosis Disease
12.10.2 Tumor Disease
12.10.3 Others
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Market Size Forecast by Type
13.6.1 Natural Hirudin
13.6.2 Recombinant Hirudin
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Market Size Forecast by Applications
13.10.1 Thrombosis Disease
13.10.2 Tumor Disease
13.10.3 Others
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Hirudin Market: Competitive Dashboard
14.2 Global Hirudin Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 The Medicines Company
14.3.2 Keyken
14.3.3 Minapharm
14.3.4 Abbott
14.3.5 SALUBRIS
14.3.6 Pfizer, Inc
14.3.7 Teva Pharmaceutical Industries Ltd
14.3.8 DUOPUTAI
14.3.9 Pentapharm
